Abstract
Nodal oligometastatic disease patients at our centre can be treated with either Cyberknife or Elekta VersaHD. We compare what the two platforms can achieve across different nodal sites, in order to improve the decision making process at MDT and improve patient outcomes. 20 patients treated on Cyberknife were replanned on Monaco. Due to proximal OARs, dose reduction was necessary in some patients. OAR doses, target coverage, and site treated compared, demonstrating advantages of both platforms for specific clinical cases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
